LEXICON PHARMACEUTICALS, INC. Contract Liability (Deferred Revenue)
LEXICON PHARMACEUTICALS, INC. (LXRX) had Contract Liability (Deferred Revenue) of $4.30 million as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2025-11-06
- 2025-09-30: Contract with Customer, Liability, Current $4.30M.
- 2025-06-30: Contract with Customer, Liability, Current $17.46M.
- 2024-12-31: Contract with Customer, Liability, Current $0.00.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2025-09-30 | $4.30M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $17.46M 10-Q · filed 2025-08-06 |
| 2024-12-31 | $0.00 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |